Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →A grade PMID 42260111
View analysis →This review presents an evidence-graded framework in which the osteosarcoma bone niche organizes layered immune failure and may contribute to treatment resistance and pulmonary recurrence, while distinguishing established mechanistic anchors from emerging hypotheses.
The review identifies bone-niche remodeling and myeloid-cell enrichment as comparatively supported mechanisms; it infers that temporally sequenced niche reprogramming, immune activation, and pulmonary-niche maintenance could improve antitumor immunity and reduce lung recurrence, but this strategy remains untested in the supplied record.
The report identifies a novel germline CTLA4 p.Phe56Cys loss-of-function variant in a patient with adolescent-onset autoimmune enteropathy, early-onset gastric malignancy, and systemic immune dysregulation, with partial immunologic and symptomatic improvement after abatacept.
Evidence in this record shows impaired CTLA4 dimerization and CD80/CD86 binding plus partial Treg and symptom improvement after abatacept; this supports—but does not establish—the hypothesis that CTLA4-pathway replacement with abatacept could benefit molecularly selected patients with CTLA4 haploinsufficiency and refractory immune-mediated disease.
This pooled observational analysis of 679 children enrolled across 11 cooperative-group trials found preserved long-term survival for orbital rhabdomyosarcoma overall, while identifying particularly poor outcomes among infants and patients with metastatic disease.
The evidence supports infants and patients with metastatic orbital rhabdomyosarcoma as high-risk groups with substantial unmet need; it is reasonable—but not demonstrated by this study—to hypothesize that risk-adapted intensification, novel agents, or different local-control strategies could improve their outcomes, while selected lower-risk patients may remain candidates for treatment-reduction research.
In a 115-participant prospective international pediatric oncology cohort, phase-angle Z-scores declined during the first six months of treatment, later recovered, and were associated with complication burden and circulating albumin, zinc, and selenium but not anthropometric nutritional categories.
The study provides observational evidence that phase angle tracks treatment-related physiological changes and complication burden; it supports, but does not test, the hypothesis that serial bioelectrical-impedance monitoring could identify patients who may benefit from earlier nutritional or supportive-care assessment.
In a cross-sectional CMR study of 109 pediatric leukemia patients and 40 age-matched controls, anthracycline exposure—particularly at higher cumulative doses—was associated with impaired left atrial function, altered atrial–ventricular strain relationships, and increased left atrioventricular coupling index.
The reported human imaging associations support CMR-derived atrial strain and left atrioventricular coupling as candidate markers of anthracycline-related cardiac impairment; it remains an inference, requiring longitudinal validation, that these markers could enable earlier cardioprotective intervention or chemotherapy-monitoring adjustments and thereby reduce toxicity.
Using a systematic review, Northern Ireland stakeholder research, and the Behaviour Change Wheel, the study developed a school-based HPV education and vaccination-opportunity intervention for adolescents aged 15–17, supported by professional training and a public media campaign.
The record supports that theory-guided stakeholder research identified barriers and specified an HPV vaccination intervention; it is inferred—but not yet demonstrated—that implementing this intervention could increase catch-up vaccination among unvaccinated adolescents and thereby contribute to prevention of HPV-associated cancers.
This evidence map and systematic review of 63 studies involving 6,158 children with growth hormone deficiency reports generally small or absent effects of growth hormone treatment on several metabolic outcomes, inconsistent lipid and anthropometric findings, and possible changes in selected exploratory biomarkers.
The supplied evidence supports using metabolic outcomes to guide further study and monitoring of growth hormone therapy in pediatric growth hormone deficiency; it only indirectly suggests, rather than demonstrates, that biomarkers or patient stratification could reduce treatment-related metabolic risk, and no pediatric-oncology-specific therapeutic benefit is established.
The study reports that CD155 supports both immune evasion and cell-autonomous growth in DMG models, links its silencing to reduced FOXM1 activity, and shows that the FOXM1-targeting agent Thiostrepton delays tumor growth and prolongs survival in DMG-bearing mice.
The supplied evidence shows that CD155 loss increases CD8+ T-cell-mediated killing and impairs DMG growth, while Thiostrepton has antitumor activity in mice; it therefore supports—but does not clinically validate—the hypothesis that targeting the CD155–FOXM1 axis could combine immune sensitization with direct tumor suppression in DMG.
In a retrospective single-center cohort of 40 pediatric patients with high-risk AML undergoing myeloablative allogeneic HCT in MRD-negative CR1, receipt of 3–4 rather than 1–2 pre-transplant chemotherapy cycles was not associated with statistically significant differences in survival or relapse outcomes.
The study provides observational evidence that additional chemotherapy after early MRD-negative remission may not improve post-HCT outcomes; as an inference requiring prospective validation, MRD-guided earlier transplantation could reduce unnecessary chemotherapy exposure without compromising disease control.
The record reports that estrogen-only menopausal therapy after hysterectomy was associated with lower breast cancer incidence in a meta-analysis of 10 randomized trials involving 14,282 participants and in a matched prospective cohort of 676 BRCA-variant carriers.
Evidence in the supplied record supports an association between estrogen-only therapy and reduced breast cancer risk after hysterectomy; it is an inference—not an established recommendation—that estradiol could serve as a risk-modifying strategy in selected patients, because formulation-specific evidence, overall safety tradeoffs, and confirmatory BRCA-focused trials remain insufficient.
In a standard-of-care evaluation of 94 consecutive pediatric CNS tumor resections, intraoperative Sturgeon nanopore methylation classification provided a correct diagnosis within 90 minutes in 87.2% of patients and reportedly changed the surgical strategy in 14.3%.
The reported evidence shows that rapid methylation-based classification can inform intraoperative resection decisions; it is reasonable but unproven to hypothesize that this guidance could reduce unnecessary tissue removal, incomplete resections, complications, or second-look surgery and thereby improve outcomes.
In a Michigan birth cohort, targeted sequencing of archived newborn dried blood spots identified pathogenic or likely pathogenic variants in 11 cancer-predisposition genes among 6.8% of 1,948 children who developed a solid or central nervous system malignancy by age 8, with strong gene–tumor specificity.
The study provides retrospective evidence that selected germline cancer-predisposition variants can be detected at birth; it supports, but does not test, the hypothesis that prospective newborn screening followed by risk-adapted surveillance or prevention could enable earlier diagnosis and improve outcomes.
